GVR Report cover Cancer Biomarker Market Size, Share & Trends Report

Cancer Biomarker Market Size, Share & Trends Analysis Report By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-1-68038-862-6
  • Number of Pages: 85
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Report Overview

The global cancer biomarkers market size was valued at USD 10.3 billion in 2016 and is estimated to grow at a compound annual growth rate (CAGR) of 14.3% from 2018 to 2025. Growing prevalence of malignancies coupled with increasing focus on development of targeted therapies is a major factor affirming the positive growth of this market.

Cancer is reported to be the second leading cause of mortality in the U.S. after cardiovascular disorders. Prevalence of breast, prostate, and lung malignancies has increased at a very steep rate with an estimated number of over 1,600 people being affected in the U.S. every year. In 2017, around 200,000 cases of breast cancer have been reported in the U.S.

U.S. cancer biomarkers market, by application, 2014 - 2025 (USD Billion)

U.S. cancer biomarkers market

Increasing awareness amongst patients and healthcare professionals about the importance of early diagnosis of malignancies and rising demand for personalized medicine is anticipated to provide this cancer biomarker market with high growth opportunities in the coming decade. Diagnostic biomarkers for early diagnosis enable doctors on deciding better treatment alternatives leading to successful recovery in lesser time.

In addition, increasing regulatory approval of novel drugs and diagnostics pertaining to cancer biomarkers is estimated to increase the adoption rate. For instance, in 2016, Epigenomics AG, a company involved in the development of a novel epigenetic biomarker test announced that its Epi proColon was included by the Chinese government for colorectal cancer (CRC) screening.

Type Insights

Based on type, the market is categorized into breast, prostate, colorectal, cervical, liver, and lung. Breast cancer was the largest segment in 2016. Breast, lung, and prostate cancer cumulatively held the revenue share of over 40% in 2016. Increasing awareness about early testing and growing base of target population are the key factors contributing toward dominance

On the other hand, lung cancer is expected to witness the fastest growth over the forecast period. Growing number of diagnostic tests targeting EGFR and BRAF mutations, which act as an essential biomarker for diagnosis of non-small cell lung cancer are anticipated to accentuate the segment growth.

Biomolecule Insights

Based on the biomolecule, the market is further segmented into genetic, epigenetic, metabolic, and proteomic biomarkers. Genetic biomarkers owing to their extensive usage, high-reliability rate, and easier analysis held a significant market share. Over 85% of malignancies are reported to be detected with the help of genetic and proteomic biomarkers.

Epigenetics has gained high acceptance in the field of cancer diagnostics. High amount of research is being undertaken by many players for the analysis of key epigenetic modification related to cancer for further development of biomarkers targeting drugs. Increasing collaboration between and pharmaceutical companies for the development of novel drugs targeting epigenetic biomarkers is estimated to boost the growth of this segment.

Global cancer biomarkers market, by biomolecule, 2016 (%)

Global cancer biomarkers market

Application Insights

Cancer biomolecules find application in various fields such as drug discovery and development, diagnostics, and personalized medicine. Diagnostics were the key revenue-generating application of the market pertaining to factors such as increasing development of biomarker-based oncology tests with high specificity and sensitivity.

Personalized medicine owing to its increasing demand and rising awareness amongst healthcare professionals is anticipated to witness flourishing growth rate. Moreover, growing approval for companion diagnostic tests for cancer drugs is expected to affirm market growth.

Regional Insights

North America dominated the regional segment followed closely by Europe. High adoption of innovative technology, presence of key pharmaceutical companies, established R&D infrastructure pertaining to the development of novel diagnostic products and increased demand for specific & early diagnostics are the major factors for the aforementioned dominance.

However, the Asia Pacific region owing to increasing prevalence of cancer, beneficial environment for clinical trials, and increasing government funding for supporting drug development programs is anticipated to witness lucrative CAGR over the forecast period. Moreover, growing focus of pharmaceutical companies over this region coupled with rising awareness for biomarker-based diagnosis is one of the high impact-rendering drivers for growth.

Key Companies & Market Share Insights

Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company are some of the key players of the market.

New product development, collaborative agreements with research institutes for the development of novel biomarkers and mergers & acquisitions of small players are the key strategies implemented by these players to attain a stable market position.

Recent Developments

  • In March 2023, Servier announced partnership with QIAGEN to develop new mIDH1 companion diagnostic test to support Servier’s Hemato-Oncology Portfolio. It is a step towards the development of a new companion diagnostic test that can be used to identify patients with acute myeloid leukemia (AML).

  • In January 2022, Illumina entered into a co-development partnership with SomaLogic to strengthen the two leading companies in the field of biomarker research. Illumina, a leader in next-generation sequencing (NGS), while SomaLogic, a leader in protein biomarker discovery will together accelerate the clinical opportunities.

Cancer Biomarkers Market Report Scope

Report Attribute


Revenue forecast in 2025

USD 33.7 billion

Growth rate

CAGR of 14.3% from 2018 to 2025

Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation                                                

Revenue in USD Billion & CAGR from 2016 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America & MEA

Country scope

U.S., Canada, UK, Germany, Japan, China, India, Brazil, Mexico, South Africa

Report coverage             

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cancer biomarker market on the basis of type, biomolecules, type, application, and region:

  • Type Outlook (Revenue, USD Billion; 2014 - 2025)

    • Breast cancer

    • Prostate cancer

    • Colorectal cancer

    • Cervical cancer

    • Liver cancer

    • Lung cancer

    • Others

  • Biomolecule Outlook (Revenue, USD Billion; 2014 - 2025)

    • Genetic Biomarkers

    • Epigenetic Biomarkers

    • Metabolic Biomarkers

    • Proteomic Biomarkers

    • Others

  • Application Outlook (Revenue, USD Billion; 2014 - 2025)

    • Drug discovery and Development

    • Diagnostics

    • Personalized medicine

    • Others

  • Regional Outlook (Revenue, USD Billion; 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Mexico

      • Brazil

    • MEA

      • South Africa

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.